Abstracts tagged "Systemic sclerosis"

Abstract Number: 0692 • ACR Convergence 2025
A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
Christopher Denton¹, Philip Yee², medha kanitkar³, Charlotte Clarke⁴, Saiam Ahmed⁴, Voon H. Ong³, Francesco Del Galdo⁵, John Pauling⁶, Marina Anderson⁷, Muditha Samaranayaka⁸, Michael Hughes⁹, Smita Bhat¹⁰, Bridget Griffiths¹¹, MAYA BUCH¹², David D'Cruz¹³, Ariane Herrick¹⁴, Madelon Vonk¹⁵, Nicholas Feemantle⁴ and Dehbi Hakim-Moulay⁴, ¹University College London, UK, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶North Bristol NHS Trust, Bristol, United Kingdom, ⁷Lancaster University and NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom, ⁸Salford Royal Hospital, Salford, United Kingdom, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁰Ninewells Hospital Dundee, Dundee, Scotland, United Kingdom, ¹¹Ninewells Hospital Dundee, Newcastle, England, United Kingdom, ¹²UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹³Kings College London, London, United Kingdom, ¹⁴The University of Manchester, UK, Aberdeen, United Kingdom, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Mycophenolate mofetil (MMF) is recommended for skin in diffuse cutaneous (dc)SSc, and for lung fibrosis in SSc, but patients with limited cutaneous (lc)SSc are…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…
Abstract Number: 0046 • ACR Convergence 2025
Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
Thomas Riley¹, Dana DiRenzo¹, Ellen Romich², Michael Levin³, Scott Damrauer³, Michael George¹, Montserrat Anguera¹, Joshua Baker¹ and Nikhil Jiwrajka¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female…
Abstract Number: L18 • ACR Convergence 2024
CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis
Wei Guo¹, Zhaohua Li², Dan Xu² and Rong Mu², ¹Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, ²Peking University Third Hospital, Beijing, China
Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Oliver Distler¹, Margarida Alves², Gerrit Toenges³ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
Abstract Number: 0712 • ACR Convergence 2024
Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis
Nouran Eshak¹, Mahmoud Abdelnabi², Jaxon Quillen¹, Michael Pham¹, Joseph Hentz¹ and Vivek Nagaraja¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is common, underdiagnosed, and manifests variably. Myocardial involvement can manifest as left heart failure with preserved or reduced…
Abstract Number: 0963 • ACR Convergence 2024
Stratification According to Autoantibody Status in Systemic Sclerosis Reveals Distinct Molecular Signatures
Bénédicte ROUVIERE¹, Christelle Le dantec², Eléonore Bettacchioli³, Lorenzo Beretta⁴, Céline Cao², Christophe Jamin², Jacques-Olivier Pers⁵, Nathan Foulquier², Martin Kerick⁶, Javier Martin⁶, Marta Alarcon-Riquelme⁷, Claire de Moreuil⁸, Divi Cornec³ and Sophie Hillion², and PRECISESADS Clinical Consortium, PRECISESADS Metabolomic Study Group, ¹CHRU de Brest, LBAI. UMR 1227, University of Brest, Brest, France, ²LBAI. UMR 1227, University of Brest, Brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France, ⁴Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, ⁵University of Brest, Brest, France, ⁶Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Spain, Granada, Spain, ⁷Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁸Service de médecine interne, CHU de Brest, Brest, France
Background/Purpose: Systemic sclerosis is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient groups further…
Abstract Number: 1570 • ACR Convergence 2024
Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung
Sunhwa Kim¹, Yingtao Bi², Vishal Kakkar³, Rebecca Ross⁴ and Francesco Del Galdo³, ¹AbbVie, South San Francisco, CA, ²Abbvie, Worcester, MA, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease with variable clinical presentations and progression rates. Accurate patient stratification is crucial for optimizing treatment strategies.…
Abstract Number: 1687 • ACR Convergence 2024
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Ioannis Parodis¹, Dionysis Nikolopoulos², Julius Lindblom³, Denis Lagutkin³, Lorenzo Beretta⁴, Maria Orietta Borghi⁵, Janique Peyper⁶, Guillermo Barturen⁷, Per-Johan Jakobsson³, Marta Alarcon-Riquelme⁸, Natalia Sherina³ and Helena Idborg⁹, and PRECISESADS Clinical Consortium, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁵Università degli Studi di Milano Statale, Milano, Italy, ⁶Sengenics Corporation Pte Ltd, Singapore, Singapore, ⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁸Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁹Karolinska Institutet, Solna, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by the production of a multitude of autoantibodies (abs). The diagnosis of SLE is supported by the presence…
Abstract Number: 1829 • ACR Convergence 2024
Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis
Philip Yee¹, Medha Kanitkar², Kristina Clark³, Voon Ong¹ and Christopher Denton⁴, ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University College London, Northwood, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) displays significant heterogeneity. Those with limited cutaneous systemic sclerosis (lcSSc) experience significant systemic organ involvement similar to those with diffuse cutaneous…
Abstract Number: 2447 • ACR Convergence 2024
Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Roberto D'Alessandro¹, Stefano Rodolfi², Alix Calot¹, Louis Bébéar³, Corrado Campochiaro⁴, Veronica Codullo⁵, Francesco Del Galdo⁶, Ivan Castellvi Barranco⁷, Elisabetta Zanatta⁸, Silvia Bellando Randone⁹, Goncalo Boleto¹⁰, Loic Raffray¹¹, Emmanuel Chatelus¹², Patrice Cacoub¹³, Alexandre Le Joncour¹³, Paolo Airò¹⁴, cristiana sieiro santos¹⁵, Alain Lescoat¹⁶, Jérôme Avouac¹⁷, Christopher Denton¹⁸ and Yannick Allanore¹⁹, ¹Rheumatology Department, Cochin Hospital, Université Paris Cité, APHP, Paris, France, Paris, France, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, UK, London, United Kingdom, ³Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France., Bordeaux, France, ⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁵Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁶University of Leeds, Leeds, United Kingdom, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Unit of Rheumatology, Padova University, Padova, Italy, ⁹Department of Experimental and Clinical Medicine University of Florence Division of Rheumatology Scleroderma Unit, Careggi Hospital Florence, Italy, Florence, Toscana, Italy, ¹⁰Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ¹¹CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, 75013 Paris, France, Paris, France, ¹⁴Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁵Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁶Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France, rennes, France, ¹⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ¹⁸University College London, Northwood, United Kingdom, ¹⁹Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France
Background/Purpose: Anti-fibrillarin (AFA) auto-antibodies are rarely found in Systemic Sclerosis (SSc). Beyond the ethnic association with a higher prevalence in patients of Black ethnicity, the…
Abstract Number: 2530 • ACR Convergence 2024
Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis
Theodoros Ioannis Papadimitriou¹, Prashant Singh², Arjan van Caam³, Madelon Vonk⁴, Irene E. van der Horst-Bruinsma⁵, Peter van der kraan³, Erik Aarntzen⁶, Martijn Huijnen⁷, Hans Koenen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ³Radboudumc, Department of Rheumatology, Nijmegen, Netherlands, ⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Radboudumc, Department of Medical Imaging, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands
Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…
Abstract Number: 0680 • ACR Convergence 2024
Clinical Correlates of Physical and Mental Health in Early Systemic Sclerosis: Data from the Collaborative National Quality and Efficacy (CONQUER) Registry
Ashima Makol¹, Isha Lamba², Dinesh Khanna³, John VanBuren⁴, Angela Child⁴, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Kimberly Lakin¹³, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Carrie Richardson¹⁸, Nora Sandorfi¹⁹, Ami Shah²⁰, Ankoor Shah²¹, Brian Skaug⁵, Virginia Steen²², Elizabeth Volkmann²³ and Jessica Gordon²⁴, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, ³University of Michigan, Ann Arbor, MI, ⁴University of Utah, Salt Lake City, UT, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Stanford University, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ¹³Hospital for Special Surgery, New York, NY, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Columbia University, New York, NY, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern Memorial Hospital, Chicago, IL, ¹⁸Northwestern University, Chicago, IL, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ²¹Duke University, Durham, NC, ²²Georgetown University School of Medicine, Washington, DC, ²³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, ²⁴Division of Rheumatology, Weill Cornell Medical College, New York, NY
Background/Purpose: Early years of Systemic sclerosis (SSc) are typically the period of peak disease activity and associated with greater pain, fatigue, sleep disturbance, physical impairment,…
Abstract Number: 0781 • ACR Convergence 2024
An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD
Takanori Sasaki¹, Ye Cao², Kathryne Marks³, Richard Ainsworth⁴, Kim Taylor⁵, Nunzio Bottini⁴, Mehreen Elahee⁶, Mari Kamiya³, Edy Kim⁶, Francesco Boin⁴ and Deepak Rao⁷, ¹Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵University of California, San Francisco, CA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify circulating immune cells associated…
Abstract Number: 0966 • ACR Convergence 2024
CDDO-Me Attenuates Pro-fibrotic Activation in Macrophages and Fibroblasts in Systemic Sclerosis
Heetaek Yang¹, Chanhyuk Park², Chen-Yu Wang³, Emily Morris⁴, Karen Liby⁵, Michael Whitfield⁶ and Patricia Pioli², ¹Dartmouth College, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth College, Enfield, NH, ⁵Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is characterized by dysfunctional immune activation, oxidative stress, and fibrosis. In prior work, we have shown that SSc macrophages (MØs) have…

« Previous Page
1
…
8
9
10
11
12
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].